Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1988-12-09
1991-01-29
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514412, 514428, 514561, 514562, 514566, 514568, A61K 3141, A61K 3140, A61K 31195
Patent
active
049887246
ABSTRACT:
Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in the detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specific polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red blood cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed.
Also disclosed are parenteral nutritional formulations which include both citrulline and ornithine which have an arginine concentration of less than about 0.10% by weight final concentration. These formulations inhibit tumor growth and are particularly suited to provide nutritional support for patients with malignant disease. These formulations act to modify the tumor cells ability to compete with normal host tissue for nutrients by modifying the specific content of amino acids administered to the patient. The exact mechanism by which such a formulation alters tumor metabolism is not known, but it has been shown that some of the described formulations result in a reduced rate of tumor cell growth when compared to standard arginine-containing TPN solutions. A method for inhibiting tumor growth and a process for preparing the tumor-inhibiting formulation are also described.
REFERENCES:
patent: 3832465 (1974-08-01), Ghadimi
patent: 3950529 (1976-04-01), Fischer et al.
Nishioka et al., (1988), Int. J. Cancer, 42: 744-747.
Byus et al., (1987), Proceedings of AACR, 28: 158 (#630).
Garewal et al. (1988), Cancer Research, 48: 3288-3291.
Majumdar et al., (1987), Life Sciences, 41: 961-966.
Malo et al., (1987), Experientia, 44: 251-252.
Morris, J. (1985), J. Nutr. 115: 524-531.
Seidel et al., (1985), Am. J. Physiol, 249: G434-G438.
Luk et al., (1984), J. Clin. Invest., 74: 698-704.
Lundell et al., (1986), Scand. J. Gastroenterology, 21 (7):829-832.
J. L. Rombeau & M. D. Caldwell (eds.), in Parenteral Nutrition, 2: 100-134, (1986).
Braun Amino Acid Suppliers, Combiplasmal.RTM. S-3,5, Aminoplasmal Paed.
Salvia Amino Acid Suppliers, Aminomel.RTM. 10X-E Saliva.
Phimmer Amino Acid Suppliers, Comafusion.RTM. Llepar.
Grossie et al. (1986), Cancer Research, 46:3464-3468.
Ota et al., (1986), Int. J. Cancer, 38:245-249.
Poedikayal et al., J. Nutrition, 116 (4), pp. 545-551, 1986, Biological Abstracts, vol. 82, 1986, Abstract 26473.
Ajani Jaffer
Grossie, Jr. Bruce
Nishioka Kenji
Ota David M.
Board of Regents , The University of Texas System
Shah Mukund J.
Ward E. C.
LandOfFree
Methods and improved formulations for the determination and trea does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and improved formulations for the determination and trea, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and improved formulations for the determination and trea will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-814196